Navigation Links
Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
Date:9/30/2009

repeated injections.

About ITCA 650

ITCA 650 therapy for type 2 diabetes consists of DUROS continuous delivery of exenatide. The DUROS delivery technology comprises the patented DUROS device, a matchstick-size miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time. The DUROS technology can deliver up to a full year of therapy from a single ITCA 650 insertion. Unlike other extended delivery technologies, such as polymers or albumin fusions, DUROS delivery allows for steady-state drug delivery upon insertion and near immediate withdrawal of therapy to manage side effects, if required. Exenatide, the active agent in ITCA 650, has been approved in the US, Europe and many other markets and is currently marketed as a twice-daily self-injection therapy for type 2 diabetes.

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. Intarcia is pursuing clinical stage development programs for type 2 diabetes and hepatitis C.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc. DUROS is a registered trademark of ALZA Corporation licensed to Intarcia Therapeutics, Inc. in certain fields. Byetta is a registered trademark of Amylin Pharmaceuticals, Inc.

    MEDIA CONTACT
    Intarcia:
    James Ahlers
    Intarcia Therapeutics, Inc.
    (510)782-7800
    <
'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
7. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
8. Nile Therapeutics, Inc. Adds to Executive Management Team
9. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
10. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
11. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... JUPITER, Fla. , July 30, 2014 /PRNewswire/ ... global biotechnology company whose patented and proprietary technologies ... enzymes and other proteins for the bioenergy, bio-based ... the appointment of Thomas "Tom" Dubinski as Vice ... responsible for leading the financial and information technology ...
(Date:7/30/2014)... , July 30, 2014   Epic Sciences, ... and develops novel diagnostics to personalize and advance the ... of Gregory T. Lucier as chairman of ... and CEO of Life Technologies (formerly Invitrogen). Mr. Lucier ... Epic commercializes its circulating rare cell analysis platform with ...
(Date:7/30/2014)... , July 30, 2014  RXi ... a biotechnology company focused on discovering, developing ... medical needs using RNA-targeted technologies, today announced ... with RXI-109, for the reduction of recurrence ... surgery, has been initiated. Logo ...
(Date:7/30/2014)... Connecticut Center for Advanced Technology, Inc. (CCAT), ... Conn., was awarded a Rural Business Enterprise Grant (RBEG) ... will determine the feasibility of implementing an alternative ... Development provided $53,000 for CCAT under the Rural Business ... the feasibility study in fiscal year 2014. , Phase ...
Breaking Biology Technology:Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... Senomyx, Inc.,(Nasdaq: SNMX ) will release its ... before the opening of the U.S. financial,markets. The Company ... Internet,broadcast that will provide a business update and a ... at 11:00 a.m. Eastern Time (8:00 a.m.,Pacific Time)., ...
... Oct. 20 GeoVax Labs, Inc. (OTC,Bulletin Board: ... for diseases caused by HIV-1 (Human Immunodeficiency Virus),and ... both DNA and,MVA components of its AIDS vaccine ... use in the upcoming Phase 2a human clinical ...
... with Industry to Educate,Promote PRV Program-, WASHINGTON, ... today announced its support of the US Food ... Industry on Priority,Review Vouchers. The Priority Review Voucher ... the development of drugs and vaccines for,neglected tropical ...
Cached Biology Technology:SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008 2GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial 2GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial 3FDA Issues Draft Guidance on Priority Review Vouchers 2
(Date:7/30/2014)... CHAMPAIGN, Ill. Scientists are searching through a massive ... more than 50 years ago, and the effort is ... world they inhabited. , When the collection is fully ... will be the largest unbiased Dominican amber collection in ... most striking discovery thus far is that of a ...
(Date:7/30/2014)... Wallerian degeneration is a subject of major interest ... differentially regulated during the distinct stages of Wallerian ... differentiation and dedifferentiation. Although gene expression responses in ... peripheral nerve injury are known, differences in gene ... unclear. Dr. Dengbing Yao and co-workers from Nantong ...
(Date:7/30/2014)... of the roughly 3,000 pieces is still in its ... results will be of major significance. "Amazingly often, we ... in Fushun amber that we found in Baltic amber," ... The Baltic amber comes from the Baltic Sea region, ... in finds are, e.g., the coastal regions of Mecklenburg, ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2Chinese mosquitos on the Baltic Sea 2
... October 23, 2013 A promising technique for treating ... may lead to new treatments to prevent blindness, according to ... Jolla, California. The studies involved controlling the actions ... to be "junk" but are now known to fine-tune gene ...
... have found out which molecular mechanisms decide about the ... for the import of proteins into specific cell components, ... receptor remains active or is broken down after the ... regulation of the protein import into peroxisomes has been ...
... simply cannot do without lasers. We use them to print ... car components, survey roads, monitor our bloodstream, and even remove ... for Applied Solid State Physics IAF in Freiburg have developed ... a particular type of infrared laser forms the ...
Cached Biology News:New eye treatment effective in laboratory tests 2New eye treatment effective in laboratory tests 3New eye treatment effective in laboratory tests 4The yin and yang in the life of proteins 2Lasers offer an automated way to test drinking water 2Lasers offer an automated way to test drinking water 3
... The PROTEAN II XL cell, wide format, is used ... x 20 cm gels and requires 1.2 L of ... unit and the 2.0 mm IPG conversion kit, which ... and includes 2 sets of IPG clamps, 2 sets ...
... been developed with the drug discovery process ... sensitivity and performance, Safire is the ideal ... development and high throughput screening. Safire is ... that offers a range of high speed ...
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
Biology Products: